ISPE Guide - Advanced Therapy Medicinal Products - Autologous Cell Therapy 2021 PDF

Full title and description

ISPE Guide: Advanced Therapy Medicinal Products (ATMPs) – Autologous Cell Therapy (2021). A practical industry guide focused on the development and design of manufacturing facilities and supporting systems for autologous cell therapies, with content intended to help engineers, facility planners, quality and regulatory teams align process, facility attributes, utilities, HVAC, and supply chain for parenteral autologous ATMP production.

Abstract

This ISPE Guide provides a comprehensive, practice-oriented reference for producing autologous cell therapies. It explains the product–process–facility relationship specific to autologous workflows, offers facility layout and cleanroom considerations, GMP and quality risk management approaches, technology-transfer and supply-chain considerations, equipment and isolator strategies, and appendices with regulatory and glossary references. The Guide is intended to reduce rework and accelerate robust facility design for personalized cell therapies.

General information

• Status: Published guidance document (industry guide).
• Publication date: December 2021 (ISPE announcement 9 December 2021).
• Publisher: ISPE (International Society for Pharmaceutical Engineering).
• ICS / categories: Advanced therapy medicinal products; biotechnology & cell therapy manufacturing; pharmaceutical engineering; facility design and GMP guidance.
• Edition / version: First edition (2021).
• Number of pages: 140 pages (ISPE bibliographic record / repository listing).

Scope

This Guide focuses on autologous cell therapy manufacturing for parenteral use and on facility development and design considerations that enable compliant, safe, and efficient manufacture at the small- to mid-scale workflows typical of autologous products. It addresses GMP compliance and quality risk management, facility layout and segregation, cleanroom and HVAC approaches, isolator and closed-system strategies, process transfer and validation considerations, cold chain and sample storage, and interactions with regulatory expectations. The Guide is written primarily for manufacturing facilities rather than point-of-care procedures performed entirely within surgical suites or purely clinical settings.

Key topics and requirements

• Product–process–facility alignment for autologous workflows (single-patient batches, track-and-trace, kitting, labeling).
• GMP compliance and a risk-based quality framework tailored to small-batch, patient-specific manufacturing.
• Facility layout, segregation strategies, and architectural considerations to prevent cross-contamination and mix-ups.
• Cleanroom classes, HVAC design principles, airflow patterns, and environmental monitoring suited for cell therapy operations.
• Equipment approaches: isolators, closed systems, single-use technologies, automation and integration trade-offs.
• Technology transfer, process qualification, validation planning and batch-release considerations specific to ATMPs.
• Supply chain, cold chain, sample storage and chain-of-identity/chain-of-custody controls for patient-derived materials.
• Regulatory alignment and reference to evolving agency guidance (FDA, EMA, PIC/S) and standards used in facility and process justification.

Typical use and users

Primary users include facility designers and engineers, process and manufacturing leads, quality assurance and validation teams, regulatory affairs specialists, CDMOs and CMOs developing autologous manufacturing capacity, and hospital/academic teams planning point-of-care or in-hospital manufacture. The Guide is used during planning, design, commissioning, technology transfer, and early commercial scale-up phases to inform decisions that balance patient-specific workflow constraints with GMP requirements.

Related standards

Commonly referenced or complementary documents and standards include: EU GMP (including Annexes and PIC/S guidance for ATMPs), FDA CMC and gene/cell therapy guidance, ISO cleanroom standards (ISO 14644 series), ISPE Baseline and other ISPE Good Practice guides, and regional ATMP-specific guidance (EMA/PIC/S). The Guide positions facility recommendations to align with these regulatory and standards frameworks.

Keywords

ISPE Guide; ATMP; autologous cell therapy; facility design; cleanrooms; HVAC; isolators; GMP; quality risk management; chain of identity; single-use; technology transfer; validation; parenteral cell therapy.

FAQ

Q: What is this standard?

A: It is an ISPE industry Guide (non‑regulatory guidance) titled "Advanced Therapy Medicinal Products (ATMPs) – Autologous Cell Therapy" that provides practical recommendations for designing and operating facilities to manufacture autologous cell therapies.

Q: What does it cover?

A: The Guide covers facility layout and segregation, cleanroom and HVAC considerations, equipment and isolator strategies, GMP and quality risk management applied to patient‑specific batches, technology transfer, validation planning, cold-chain and sample storage, and regulatory context relevant to autologous ATMP manufacture.

Q: Who typically uses it?

A: Facility engineers, manufacturing/process leads, QA/validation teams, regulatory affairs professionals, CDMOs/CMOs, and hospital or clinic teams planning in‑house cell therapy operations.

Q: Is it current or superseded?

A: The Guide was published in December 2021 (first edition). It remains a foundational industry reference for autologous facility design; ISPE has since published additional ATMP guides (for example, an allogeneic ATMP guide in 2024 and subsequent ATMP-related Good Practice Guides) that build on and complement the autologous Guide. Users should check for newer ISPE publications or updates when planning major new facilities.

Q: Is it part of a series?

A: Yes — it is part of ISPE’s growing set of ATMP guidance documents and Good Practice Guides addressing different modalities and topics (autologous, allogeneic, rAAV/gene therapies, equipment design, validation, etc.), intended to be used together as complementary references.

Q: What are the key keywords?

A: Autologous, ATMP, cell therapy, GMP, cleanroom, isolator, single‑use, facility design, HVAC, chain of identity, validation, technology transfer.